NCT04685070进行中（未招募）2 期
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer: A Single-Arm, Open-Label, Phase II Clinical Trial
Shanghai Pulmonary Hospital, Shanghai, China1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2021年12月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) Almonertinib (HS-10296) as neoadjuvant and adjuvant therapy for potential resectable stage III EGFR mutation-positive Non-small Cell Lung Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;
- •At stage III (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS;
- •No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);
- •With the feasibility to receive radical surgery ;
- •Good lung function that could tolerate surgical treatment;
- •Aged 18-75 years;
- •At least one measurable tumor foci (the longest diameter measured by CT shall be > 10 mm);
- •Other major organs shall function well (liver, kidney, blood system, etc.):
- •ECOG PS score shall be 0-1;
- •The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;
- •The patient shall sign the Informed Consent Form.
排除标准
- •The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;
- •The patient suffered from other cancers besides NSCLC (except cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor [including Ta and Tis]) within 5 years before the trial;
- •The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure [≥ Grade II specified by New York Heart Association (NYHA)], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;
- •The patient is a carrier of active hepatitis B, hepatitis C or HIV;
- •The patient suffers from severe or new-onset gastrointestinal diseases with diarrhea as the main symptom;
- •The patient has had or is currently suffering from cardiovascular malformation;
- •The patient has had or is currently suffering from interstitial lung disease;
- •The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;
- •The patient is allergic to afatinib or its any excipients;
- •The patient suffers from nervous system diseases or mental diseases and cannot keep compliance with the trial;
- •The patient has any malabsorption condition;
- •The female patient is in pregnancy or lactation period;
- •There are any conditions under which the investigator considers the patient is not suitable to be enrolled.
研究组 & 干预措施
HS-10296 (Almonertinib)
Experimental
干预措施: HS-10296 (Almonertinib) (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: up to 4 months
ORR is defined as the proportion of patients who have completed the neoadjuvant treatment before operation and have achieved CR or PR as confirmed by CT evaluation in all patients.
次要结局
- Major pathologic response (MPR)(up to 5 months)
- Overall survival (OS)(up to 60 months)
- Treatment-related adverse events(up to 13 months)
- Pathological complete response rate (pCR)(up to 24 months)
- Event free survival (EFS)(up to 60 months)
- R0 resection rate(up to 6 months)
研究者
Peng Zhang
Director of thoracic department
Shanghai Pulmonary Hospital, Shanghai, China
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain MetastasesLung CancerNCT04808752Zhejiang Cancer Hospital63
进行中（未招募）
2 期
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryStage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung CancerStage II Non-Small Cell Lung CancerStage IIA Non-Small Cell Lung CancerStage IIB Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerNCT03433469University of California, San Francisco27
进行中（未招募）
2 期
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C MutationLung CancerNCT05118854M.D. Anderson Cancer Center13
进行中（未招募）
2 期
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsHER2-positive Breast CancerNCT05426486Caigang Liu136
招募中
2 期
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerNon-Small Cell Lung CancerNCT06623136Elpiscience (Suzhou) Biopharma, Ltd.40